PMID- 19133008
OWN - NLM
STAT- MEDLINE
DCOM- 20090305
LR  - 20151119
IS  - 1600-0463 (Electronic)
IS  - 0903-4641 (Linking)
VI  - 116
IP  - 12
DP  - 2008 Dec
TI  - Choice of endothelial marker is crucial for assessment of bone marrow microvessel 
      density in chronic lymphocytic leukemia.
PG  - 1058-62
LID - 10.1111/j.1600-0463.2008.00987.x [doi]
AB  - Angiogenesis is a potential prognostic factor in chronic lymphocytic leukemia 
      (CLL). Elevated circulating levels of angiogenic factors in CLL have been 
      repeatedly reported. Nevertheless, the issue of bone marrow neovascularization in 
      CLL remains controversial, partly due to limited number of published studies, 
      different methods of assessing microvessel density (MVD) and small patient 
      cohorts. Moreover, there are very scarce data regarding the relationship of 
      marrow angiogenesis to prognostic markers in CLL. Our objectives were: 1. To 
      assess bone marrow MVD in CLL using two different monoclonal antibodies and a 
      reproducible method of MVD quantification; 2. To examine the possible association 
      of marrow MVD and clinical course, pattern of marrow infiltration, Rai stage, 
      cytogenetic abnormalities detected by fluorescence in situ hybridization (FISH), 
      and mutation status of immunoglobulin heavy chain variable region (IgVH). MVD was 
      higher using CD34 vs vWF antibody (p<0.0001). However, no MVD differences were 
      detected between CLL subgroups subdivided according to the above-mentioned 
      prognostic factors. In conclusion, MVD assessment using anti-CD34 resulted in 
      higher MVD counts than when using anti-vWF antibody. No association of MVD with 
      any prognostic factors was observed, possibly due to the limited patient cohort. 
      As the need for bone marrow trephine biopsies in CLL is significantly decreasing, 
      a standardized method of neovascularization assessment is required to enable 
      possible multicentre studies in order to conduct larger investigations and 
      thereby shed more light on the real clinical significance of bone marrow 
      angiogenesis in CLL.
FAU - Smolej, L
AU  - Smolej L
AD  - 2nd Department of Internal Medicine, Department of Clinical Hematology, 
      University Hospital and Medical School, Hradec Kralove, Czech Republic. 
      smolej@seznam.cz
FAU - Kasparova, P
AU  - Kasparova P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - APMIS
JT  - APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
JID - 8803400
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD34)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (von Willebrand Factor)
SB  - IM
MH  - Antibodies, Monoclonal/immunology
MH  - Antigens, CD34/analysis
MH  - Biomarkers, Tumor/*analysis
MH  - Bone Marrow/*blood supply/*pathology
MH  - Endothelium, Vascular/immunology/*pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*pathology
MH  - Microvessels/immunology/pathology
MH  - Neoplasm Staging
MH  - Neovascularization, Pathologic/*diagnosis
MH  - von Willebrand Factor/analysis
EDAT- 2009/01/10 09:00
MHDA- 2009/03/06 09:00
CRDT- 2009/01/10 09:00
PHST- 2009/01/10 09:00 [entrez]
PHST- 2009/01/10 09:00 [pubmed]
PHST- 2009/03/06 09:00 [medline]
AID - APM987 [pii]
AID - 10.1111/j.1600-0463.2008.00987.x [doi]
PST - ppublish
SO  - APMIS. 2008 Dec;116(12):1058-62. doi: 10.1111/j.1600-0463.2008.00987.x.